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     This article reviews the recently published data on the diagnosis of cancer with proteomics, including the 
major proteomics technologies and promising strategies for biomarker discovery and development.  Most of 
the tumor markers are proteins that either numerically increase in response to the alteration of cancer 
conditions or are produced by cancer cells. However, they are natural compounds ordinarily available in the 
typical cells to a little extent what are affected by increase of expression due to cancer and its intensity in 
blood, body fluids or tissues. Tumor markers are substances normally available in body fluids such as serum, 
urine, blood, and tissues that increase in the desired tissue of cancer patients. Most of tumor markers are 
proteins that either are produced in response to changes in cancer conditions or are made by the cancer cells. 
However, most of tumor markers are among the natural compounds of normal cells present in normal 
conditions in the cell in small amounts and are affected by increase of expression, due to cancer and their 
levels in the blood, body fluids or tissues.  
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INTRODUCTION 
Tumor markers are substances available in body 
fluids such as blood, urine, serum and tissues that 
are increased in patients with cancer in different 
tissues. Most of tumor markers are proteins that 
either are increased in response to changes in 
cancer conditions or are made by the cancer cells. 
However, most of tumor markers are among the 
natural compounds of normal cells present in 
normal conditions in the cell in small amounts 
that are affected by increase of expression due to 
cancer and their levels in the blood, body fluids or 
tissues [1]. Tumor marker may be considered as a 
molecule determining the cancer risk or even 
provides us with the information about cancer risk 
and behavior such as metastases, cancer spread, 
and cancer recurrence and back [1]. Tumor 
markers are divided into two main classes of 
“tissue-specific” and “cancer-specific”. The first 
class tumor markers are related to which tracing 
them indicates presence of tumor in tumor tissue 
in the body. Some tumor markers like CEA 
(Carcinoembryonic Antigen), CA125 (Cancer 
Antigen 125), and CA19-9 (Cancer Antigen 19-9) 
can also be applied in treatment, follow-up, 
evaluating the extent of tumor spread and 
response to therapy. Cancer-specific class is 
related to the tumor markers which tracing them 
indicates presence of tumor tissue in a particular 
tissue where the tumor has spread. These types of 
tumor markers are likely to increase in non-tumor 
conditions as well. PSA (Prostate Specific 
Antigen), GCC (Guanylyl Cyclase C), AFP 
(Alpha-fetoprotein), and beta-globulin are in this 
class [2]. 
Generally, there are five main types of tumor 
markers [3]: 
1.Enzymes: Alkaline phosphatase, phosphatides, 
PSA, and etc. 
 
Journal of Paramedical Sciences (JPS)                           Winter 2014 Vol.5, No.1 ISSN 2008-4978 
106 
 
2.Tissue receptors: GCC, ER (Estrogen 
Receptor), PR (Progestrone Receptor), and etc. 
3.Antigens: CA125, CA19-9, CEA, and etc. 
4.Oncogenes: Ras, Myc, and etc. 
5.Hormones: HCG (Human Chorionic 
Gonadotropin), calcitonin, and etc. 
 
History of tumor markers 
    The first modern tumor marker used to check 
out cancer was HCG that was used for pregnancy 
test. High concentrations of this marker in the 
blood may be a sign of cancers related to the 
placenta so-called Gestational Trophoblastic 
Disease (GTD). Some types of uterine and 
testicular cancers produce this marker where germ 
cells are affected [4]. 
The purpose of researches in the field of tumor 
markers is to reach to a point that any type of 
cancer could be diagnosed by a blood (or urine) 
test. In addition to detecting the cancer at early 
phases, this simple blood test can prevent millions 
of deaths each year. The first success in finding a 
blood test for detect a cancer was achieved in 
1965 when Carcinoembryonic Antigen (CEA) 
was detected in the blood of patients with colon 
cancer. By late 1970s, several other blood tests 
for various types of cancer were discovered 
including marker CA19.9 for colon and pancreatic 
cancer, CA15-3 for breast cancer and CA125 for 
uterine cancer. After them, some markers were 
identified that were not investigated further, 
because they had no benefit in compare with 
recent markers [5]. However, due to the following 
reasons, none of these markers met the main goal 
in cancer diagnosis at early phases: 
1.Most people have a small amount of this marker 
in their blood; therefore, this it is difficult to 
diagnosis the cancer in early phases. 
2.The amount of these markers significantly goes 
higher than normal when too much time has 
passed since the onset of the cancer. 
3.The elevated level of these markers in the blood 
of some patients is not observed though they are 
affected by cancer. 
4.High level of these markers in the blood may 
not be only due to cancer; for example, CA125 
also rises in women with gynecologic problems. 
The most important and only marker used for 
screening is Prostate Specific Antigen (PSA) that 
has been used since the early 1990s as a screen 
marker for early phases of prostate cancer; it is 
now used because of two reasons: firstly, this 
marker is made only by prostatic cells and 
therefore, diagnosis of this marker is an indicator 
of prostatic problems; secondly, this marker is 
increased at the onset of cancer that can help to 
diagnose the cancer at the early phases [6]. 
 
Applications of Tumor Markers 
    Most tumor markers can be potentially used in 
any of the items listed below for diagnosis, 
prevention and in some cases even for treatment. 
Here are some applications of tumor markers: 
1.Screening of malignant tumors in the initial 
phase:  
Despite the limitations and lack of specificity for 
tumor markers in the initial phases of formation, 
several tumor markers currently have the potential 
to be used in the screening tests, including 
Vanillylmandelic Acid (VMA) and Homovanellic 
Acid in the screening of infants suffering from 
neuroblastoma [7], AFP for cancers of hepatic 
cells, CA125 for women with uterine cancer and 
PSA marker for prostate cancer. Nevertheless, 
study on none of these markers could reduce 
mortality in patients with malignant tumors [8, 9, 
and 10]. 
2.Help to cancer diagnosis:  
One of the important problems in cancer 
diagnosis is concerning identification the primary 
tissue in a metastatic tumor, because identification 
of primary tissue is essential in many cancers for 
management the patient and treatment. In some 
cases, despite the analysis of pathologic results, 
medical examinations, routine blood and serum 
analysis, and X-ray examinations they are still 
unable to identify the primary tumor tissue. 
Fortunately, in such cases, several tumor markers 
have been identified which their determination in 
the blood and serum may help to identification of 
primary tissue [11]. The production rate of HCG 
marker increases in the case of gestational 
choriocarcinoma, AFP and HCG markers in 
germinal tumors, PSA in prostate cancer, and the 
amount of CA15-3 marker in breast cancer [12]. 
According to the statement of National Cancer 
Center Network (NCCN) and European Society 
of Medical Oncology (ESMO), the level of AFP, 
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HCG and PSA markers should be measured in the 
men who have cancer with unknown origin and 
primary tissue; and according to the same 
statement, the level of AFP, HCG, CA125, 
estrogen receptor, progesterone receptor and 
HER2 (Human Epidermal Growth Factor 
Receptor 2) should be measured in women [13]. 
3.Prognosis prediction:  
Prognostic markers are the factors may predict the 
outcome of a cancer or a patient when he/she is 
not treated e.g. adjuvant therapy. Predictive 
markers are the factors indicating the response or 
sensitivity of a cancer to the therapeutic agents 
during the treatment [14]. The common prognosis 
factors for malignant tumors include tumor size, 
tumor grade, and number of involved 
metastasized lymph nodes; furthermore, tumor 
markers can be considered as a prognosis factor 
for malignant tumors if they possess the following 
characteristics [15]: 
Being independent of the previous common 
prognosis factors or able to provide sufficient 
information in addition to them; 
The information provided by tumor markers 
would be more accurate and more precise than the 
ones obtained from previous factor; and 
Tumor markers would be able to provide 
prognosis information in the cases that common 
clinical factors are unable to provide information. 
For example, in the patients with breast cancer of 
the negative lymph node and the patient with 
colon cancer of stage II, prognosis markers may 
distinguish between the patients who must receive 
chemotherapy and those who do not need to 
receive this therapy. 
The prognosis markers can be measured both in 
serum level and tumor tissue. The serum markers 
have this ability to identify the spread of tumor 
bulk or hidden metastases by examining their 
concentration. The most widely used tissue 
markers in this field are probably the molecules 
able to indicate the tumor spread through 
increased cell proliferation or metastatic spread in 
the tissue [16]. 
The most popular and best prognosis tumor 
markers used in clinics are AFP, HCG, and LDH. 
Another common marker is CEA in the diagnosis 
of colorectal cancer that is able to distinguish 
between the patients of stage II who are eligible to 
receive chemotherapy and those who do not need 
to receive this therapy. Two popular prognosis 
markers in the people with breast cancer of 
negative lymph node are Urokinase Plasminogen 
Activator (UPA) and Plasminogen Activator 
Inhibitor-1 (PAI-1) [17]. 
4.Post surgical care:  
One of the main applications of tumor markers is 
currently to monitor the patients’ situation after 
surgery. This is important since the timely 
diagnosis of metastatic and returning the disease 
after surgery improves the chance of recovery or 
treatment results [7]. Thyroglobin (TG) is one of 
the markers in patients with advanced thyroid 
carcinoma. Normally, the concentration of this 
marker in the people serum is not measurable and 
its increase may be sign of metastatic or return of 
thyroid cancer in the patients when it is detectable 
and is observed in the patients’ serum [18]. 
Another most widely used markers in the review 
of recovery process after surgery of patients with 
colorectal cancer is CEA. The recent 
investigations has shown that serial evaluation of 
this marker in patients’ serum can indicate the 
return of cancer and its metastasis in patient after 
surgery with a sensitivity and specificity of about 
%80 and %70, respectively. CEA is currently one 
of the most widely used markers in the review of 
colorectal cancer and also is the most applicable 
test to determine the potential of therapeutic in the 
people with returning the cancer [19]. 
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Predict the response to therapy: The predictive 
markers are very important in oncology, because 
the cancers are different in terms of response to 
therapy. Only small number of cancer patients 
benefits from the specific systemic methods; 
therefore, we will be probably able to avoid the 
unnecessary therapeutics and apply most 
beneficial therapy for patients if we could 
properly select the patients in terms of response to 
therapy. Having the accurate predictive markers 
in this field can help us to get reliable and 
accurate results. Nevertheless, only few of 
oncologic predictive markers are clinically 
useable [7]. The first of these markers in oncology 
is ER that can indicate the probability of response 
to hormone therapy in patients with breast cancer 
[20]. The new marker been introduced for patients 
with breast cancer is HER-2 that is used to check 
the patients who are treated by Trastuzumab 
(Herceptin, Roch). Trastuzumab is a monoclonal 
antibody synthesized against HER-2 [21]. 
Epidermal growth factor receptor (EGFR) is 
another predictive marker that its mutation or 
increase of expression was seen in various types 
of cancer; two therapeutic agents of monoclonal 
antibodies and tyrosine kinase inhibitors (TKIs) 
have been synthesized against this marker [22]. 
 
 Modern techniques for measuring the 
tumor markers 
    The common methods for measuring the tumor 
markers are ELISA technique for serum markers 
and Immunohistochemical technique for tissue 
markers; usage of these two techniques, we are 
now able to track one or a few markers 
simultaneously [7]. But two new techniques of 
microarray gene expression and proteomic are 
capable to track hundreds or thousands of markers 
simultaneously. According to recent 
investigations, it is claimed that use of microarray 
helps us to identification of tumors with unknown 
primary site that are similar in terms of 
morphology; it also provides beneficial and 
predictive information to evaluate the response or 
resistance of tumors to special therapy. While this 
method can measure thousands of genes at RNA 
level, proteomic method measures the markers at 
protein level [23]. There are many new proteomic 
techniques including gel electrophoresis, tissue 
microarray, antibody microarray and mass 
spectrometry (SELDI-TF), that the recent 
technique can detect different kinds of cancer 
with more remarkable specificity and sensitivity 
than existing markers [24]. 
The matter in making these techniques applicable 
is that standardization and simplification should 
be done at first and also their cost must be 
reduced to become available and usable in 
laboratory centers easily [25]. 
 
Clinical tumor markers 
    Currently, there are over 60 kinds of analytes as 
tumor marker that have been approved by 
Association of Food and Drug (AFD). Some of 
them are only for research goals, but they are 
mostly for diagnostic, screening or cancer 
evaluation purposes [26]. Here, we explain some 
more common clinical tumor markers that are 
used in laboratories as diagnostic tests. 
Alpha-fetoprotein (AFP):  
AFP is a glycoprotein, which is produced by 
developed fetuses but its amount declines in the 
blood after the birth. AFP test is primarily used to 
detect some abnormalities that occur during 
embryo development. However, in adults the 
higher level of 1000 ng/l of this marker in the 
blood is often associated with cancer. AFP test 
has been confirmed for the detection and 
evaluation of testis cancer. Also, the level of this 
marker rises in 80% of patients with hepatic cell 
carcinoma and liver cancer. The biopsy for 
evaluation of liver cell carcinoma should be 
performed when AFP levels as high as 500 ng/l 
(or higher) would be observed [27]. 
CA125:  
This marker is as kind of glycoprotein that is 
expressed by epithelial cells during embryo 
development [5]. The high amount of this marker 
is often associated with uterine cancer, so that the 
level of this marker rises in serum in 75% of the 
patients with uterine cancer. Also, the level of this 
marker increases in 50% of the patients as stage I 
and 90% of the patients with stage II and higher 
[26]. The level of marker CA125 is associated 
with the amount of tumor mass; therefore, this test 
is used to check out the return of tumor followed 
by chemotherapy [26]. In this test, the level of this 
marker is checked in patients with uterine cancer 
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every 3 months for 2 years after the therapy and 
elevated level of this marker during this 
assessment represents the return of disease in 
most cases [28]. In addition to uterine cancer, this 
marker is also used to evaluate some other 
malignant cancers such as liver cancer, lung 
cancer, breast cancer and colon cancer [4]. 
Carcinoma embryonic Antigen (CEA):  
This marker is a kind of glycoprotein that is 
expressed by normal mucosal cells. Increased 
expression of CEA is seen in adenocarcinomas 
particularly colorectal cancer [29]. The amount of 
this marker rises in 50% of colorectal cancers that 
have spread to lymph nodes and 75% of patients 
with metastasis. The highest amount of CEA is 
100 ng/ml that has been observed in patients with 
metastasis [30]. CEA marker is not suitable for 
screening test of patients with colorectal cancer 
[31]. The main role of this marker is investigating 
return of disease after receiving a suitable therapy 
in patients with colorectal cancer [30]. American 
Society of Clinical Oncology has proposed to 
assess the amount of CEA in patients with colon 
cancer stage II and III and those who are surgical 
candidates every 2 to 3 months for at least 2 
years. If we observe elevation of this marker, a 
metastasis or return may be happened [32]. The 
investigations represent that the amount of this 
marker may be mild elevated in the smokers and 
5% of healthy people [26]. 
Prostate Specific Antigen (PSA):  
It is a glycoprotein produced by epithelium cells 
of prostate and its level rises in men suffering 
from prostate cancer and any other diseases 
related to prostate [33]. PSA has been approved as 
a screening test for prostate carcinoma. Normal 
serum level of this marker is less than 4ng/l. The 
level between 4 and 10 ng/l means that it is a 
positive test, because the level of this marker goes 
higher than 4 and 10 ng/l in 20-30% and 50% of 
patients with prostate carcinoma, respectively 
[33]. The presence of metastasis can be predicted 
by PSA test [34]. In patients that the level of PSA 
is recently elevated and PSA is less than 20 ng/l, 
the probability of cancer is very rare and the 
probability of metastasis is below 2% [34]. After 
treatment of prostate cancer, PSA level should be 
controlled every 6 months for 5 years and then 
every 2 years [35]. 
 
Human Chronic Gonadotropin (HCG):  
Beta subunit of this glycoprotein marker is 
normally expressed by cells of the placenta and 
high level of this marker has been observed in 
pregnancy and cancers associated with germ cells 
and gestational trophoblastic disease [36]. HCG 
along with AFP rises in 85% of patients suffering 
from tumors related to germ cells, but the level of 
this marker rises in only 20% of patients with 
stage I; therefore, this marker is not suitable for 
screening test since it rises only in small 
percentage of patents at early stages [36]. In 
metastatic cases, the high level of AFP and HCG 
can help to diagnosis of germ cells tumors at the 
current phase of cancer [37]. The higher levels 
than 10000 ng/ml of AFP and 50000 u/ml of 
HCG at diagnosis time suggests poor prognostic 
outcome, means that the cure rate is low [38]. The 
level of these two markers is also used to assess 
the response to the therapy of patients with germ 
cells tumors. In the patients who their level of 
these two markers does not decrease appropriately 
after receiving the therapy, it is necessary to 
consider another therapy method [38]. 
 
Common cancers and tumor markers 
Breast cancer 
Nowadays, the diagnosis of breast cancer is 
accomplished in the laboratories by common 
biological parameters such as lymph node status, 
tumor size, tumor grade, malignancy rate, age and 
expression of gene HER-2 [39]. Despite this, it 
seems that to know these parameters would not be 
sufficient for precise diagnosis or proper selection 
of the patients for radiotherapy; also to estimate 
the rate of disease progression and preventing the 
return of cancer after therapy, it is necessary to 
present newer markers with higher sensitivity and 
specificity [40]. Nowadays, the only marker that 
is used for evaluation of therapy is estrogen and 
progesterone receptor (ER/PR) that is applied to 
select the patients who need to receive an 
approach for hormone therapy. Also, marker 
HER-2 is used to select the patients who should 
receive Trastuzumab (Herceptin) [39]. In the 
recent years, Tissue Inhibitor of 
Metalloproteinase 1 (TIMP1) has been proposed 
as a new prognostic marker and the marker 
assessing response to the therapy in the patients. 
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The molecular role of this marker is inhabitation 
of apoptosis in the tumor cells [39]. According to 
the investigation conducted in 2009, gene Gli1 
has been introduced as another prognostic marker 
for breast cancer [40]. During this study, the 
scientists concluded that there is a strong 
correlation between increase in the expression of 
this marker and unsuccessful therapy results in the 
patients suffering from  breast cancer, also the 
increase in the expression of this gene is 
associated with lymph node status and tumor 
stage [41]. 
Uterine cancer 
According to the various studies have been 
conducted on identifying the tumor markers of 
uterine cancer, the best known and most widely 
used marker to study and diagnosis of uterine 
cancer is CA125 that is used as a test to check out 
the therapy during and after the therapy [42]. 
However, the use of this marker has been 
restricted due to this fact that the level of this 
marker also rises in the serum of patients with 
heart failure and liver cancer [43]. Hence, the use 
of this marker, along with other common 
diagnostic methods is currently being investigated 
[44]. Therefore, there is an essential need for 
more sensitive and more specific markers beside 
CA125 for diagnosis and study of the therapy in 
patients with uterine cancer [44]. One of these 
new markers is B7-H4 that is used beside CA125 
to detect the cancer at early stages and the 
combination of these two markers together has the 
greater specificity than the marker alone. The 
increase expression of CA125 is observed in cases 
whom the tumor is malignant or has spread [45]. 
At an investigation conducted in 2007, Spondin2, 
which is a member of spondin family, and dcr3, 
which is a secretory member of TNFR, beside 
markers CA125 and B7-H2 are presented as a 
group to improve the diagnosis and detection of 
uterine cancer [46]. 
Gastric cancer 
Gastric cancer is one of the most common cancers 
in the world and there are limited biomarkers to 
check out or predict the progression of this cancer 
[47]. Molecular markers are one kind of these 
markers. CEA has been presented as the most 
widely used tumor marker for gastric cancer [48]. 
CA19-9 and CA72-4 are also among the antigen 
markers that have been presented to detect and 
check out the patients suffering from gastric 
cancer [49]. CEA and CA19-9 are most common 
tumor markers to detect and check the patients 
suffering from gastric cancer after surgery and the 
combination of these two markers causes the 
increase of sensitivity of these markers. But none 
of these two markers are sensitive enough to 
diagnose gastric cancer. At a study, these two 
markers have been reported to be more reliable 
and more important than other tumor markers for 
gastric cancer [50]. On the other hand, in an 
investigation done in 2007, M2-Pyruvate Kinase 
marker has been presented as a more accurate and 
more sensitive tumor marker than CEA, CA19-9 
and even CA72-4 to detect the esphagogastric 
patients [51]. 
Evaluation of TIMP1 gene in the serum of 
patients with gastric cancer indicated the 
sensitivity and specificity of %17 and %98 as a 
marker, respectively. Because the high sensitivity 
and specificity is required for a diagnostic marker, 
this marker is not suitable as a prognostic marker 
in the cases are at high and advanced stages. It has 
been observed that the increased expression of 
this marker has a strong association with 
progression of the cancer. According to the 
investigations and researches conducted to 
identify and introduce the tumor marker with high 
sensitivity and specificity, also the limited 
markers in this area been identified [52]. 
Colorectal cancer (CRC) 
The rapid increase of signs and molecular 
symptoms of colorectal cancer caused the 
identification of the molecular markers could help 
the therapy and diagnosis of patients. But despite 
of the assessments and identifications of different 
markers, the experts have not yet succeeded to use 
these markers as a common and routine test. 
Apart from MSI, most identified molecular 
markers have not yet been able to recognize the 
stage of CRC patients clearly and successfully 
[53]. 
Serum markers 
In recent years, various markers for the detection 
of CRC have been targeted that they could be 
measured in either serum, or blood, or stool and 
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The oldest and still most widely used marker in 
CRC patients is CEA. This marker is used in 
these patients to study the improvement of 
patients after resection of the primary tumor. 
Another major advantage of this marker is the 
early detection of recurrent and metastasis, 
particularly liver metastasis [55]. Although the 
best method for improvement and survival 
increasing of these patients is surgery, the main 
therapy of patients with metastasis is 
chemotherapy. In these patients, the CEA level 
should be measured every 2-3 months for 3 years 
[56]. 
Markers based on stool 
The most widely used test for CRC screening is the 
diagnostic test checking the presence of blood in 
stool. This test is based on the peroxidase-like 
activity of hemoglobin and immunochemical 
which evaluates the shape and position of the 
globin chain of hemoglobin [57]. Another test in 
this field is checking out the abnormal DNA 
mutants that since there is no significant and 
known gene which would be altered in CRC 
patients, a number of genes are like mutants of K-
Ras, APC, P53, BAT26, adenine tract26 and long 
DNA [58]. 
Tissue markers: 
The serum markers are preliminarily used for 
improvement and survival increasing after the 
surgery, while stool markers are mostly used for 
screening; on the other hand, the tissue markers are 
valuable in the diagnosis, therapy, and prediction 
of disease [54]. 
Thymidylate synthesis (TS) 
Thymidylate synthesis (TS) is a rare enzyme 
causes converting deoxyuridine monophosphate 
(Dump) to deoxythymidine monophosphate that is 
a necessary reaction for DNA synthesis. TS is 
widely used as a tissue marker for diagnosis and 
prediction of therapy [59]. A review of clinical 
studies has shown a correlation between high 
expression of TS in CRC patients and resistance to 
5-FU, which is a agent for chemotherapy in the 
patients. The higher TS in the patients associated 
with the poor results of chemotherapy [60]. 
Microsatellite instability (MSI) 
One of the most applicable and acceptable 
molecular markers is MSI tissue marker. 
Approximately %15 of CRC patients, who are 
potential candidates for study of MSI, indicate the 
deactivation of mismatch repair factors that causes 
increase/decrease in repeating of a repetitive 
sequence of about 5-10 nucleotides on DNA [61]. 
Based on an investigation carried out on CRC 
patients, the patients with MSI have shown the 
better results for approximately %15 in comparison 
with the patients without MSI. Moreover, the 
correlation between MSI and desired diagnosis of 
CRC patients, according to this study, might be 
because of activated lymphocytes [62]. 
Guanylyl Cyclase C (GCC) 
GCC is from the receptor family of guanylyl 
cyclase and six groups of this family have been 
identified in the mammals so far. These receptors 
are involved in secretion and the regulation of body 
fluids and electrolytes [63]. GCC is expressed in 
mucosal cells of intestine from duodenum to 
rectum and is not expressed in the outer intestinal 
tissues [64]. Expression of this receptor increases 
in the cases that colon tissue undergoes the 
transformation and metastasis and this increased 
expression has not been observed in the metastasis 
of other outer intestinal tumors [65, 66]. Various 
articles have introduced this receptor as an unique 
and specific marker to study the metastatic state 
and the improvement of CRC patients after the 
surgery [67, 68, and 69]. The spread of tumor cells 
into the peripheral blood is one of the metastatic 
cases. In an investigation carried out on the blood 
of CRC patients, this marker was observed in their 
peripheral blood and was further known as a 
specific marker to study the metastatic tumors of 
colorectal cancer as well as tracking the free tumor 
cells in the blood [70]. 
During his researches and investigations in 2008, 
Dr. Scott Waldma applied this marker to develop a 
diagnostic kit for cancer patients following by 
confirming that as a diagnostic marker for CRC 
[71]. 
Methylated genes as the new tumor 
markers 
    During the cancer process, the first defect takes 
place in genomic DNA, including molecular 
alteration of mutation, copy, move, heterozygous, 
MSI and aberrant methylated of the specific genes. 
The genes which undergo this change are proposed 
to be capable of being used as the tumor marker 
[72]. The aberrant hyper methylation of some 
specific genes at promoter region is an important 
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fact toward the formation and progression of the 
cancer. For instance, in some situations this 
aberrant methylation happens at the early stages of 
malignity of the tumor. Many investigations have 
claimed that measurement of methylation of 
promoter region of specific genes is likely to be 
beneficial in early detection of cancer, prognostic 
determination and prediction of therapeutic 
response [73]. One of the reasons to consider DNA 
as a tumor marker is that DNA is more resistance 
than RNA and also can stay unchanged longer; 
consequently, it might be a useful tool for 
laboratory studies. Furthermore, DNA could be 
copied by PCR easily; therefore, less amount of 
sample is required than mRNA and protein [74]. 
The methylation takes place at CpG region on the 
DNA. The CpG supposed to be metylated has the 
size of 0.5 to 5 kilos of the pairs. About %50 of 
mammalian genes contain CpG located in 
promoter region or first exon that are typically 
often inactive and just get methylated and activated 
in cancer conditions. The methylation of CpG in 
promoter genes is usually associated with genes 
shutdown due to the prevention and interruption of 
transcription of genes [75]. Assessment of 98 
various primary tumors indicated an average of 
about 600 aberrant methylated genes in each 
tumor. The genes methylated at early phase of 
tumorgenesis are likely to be useful to detect the 
people at risk of tumor progression or malignancy. 
However, the genes methylated in the middle of 
tumorgenesis or in the malignant stages may be 
used as prognostic marker. In addition, the 
measurement of the amount of genes methylation 
in cases that drug resistance or susceptibility is 
observed, could lead to improvement of the 
information concerning the prediction of the 
appropriate therapy [76]. The genes undergo 
aberrant methylated are suitable to be used as 
tumor marker due to three reasons. Firstly, since 
the amount of protein markers increases slightly at 
early stages of tumorgenesis and cancer, the 
evaluation of these markers in blood is difficult. 
Then, they hold diagnosis potential at early stages 
or in screening; however, the methylation of 
promoter of several genes currently exist both in 
early and advanced stages of cancer and freely 
releasing of a piece of these genes into the blood 
might be useful as a marker investigating the 
cancer at early stages or early diagnosis [77]. One 
of the other characteristics of tumor markers is 
their tissue specificity, particularly when they are 
used for diagnosis. Due to some unknown reasons, 
some genes have tissue specificity and get 
methylated in certain cancer tissues. Take for 
instance, Hmlh1 gene gets methylated in colorectal 
and gastric cancer whilst is rarely and slightly 
methylted in other types of cancer [78]. BRCA1 
gene is methylated in breast and ovarian cancer 
while PV3 and p15 are methylated in most of the 
hematologic malignancies. This sort of methylation 
also helps the identification of metastatic tumors 
with unknown primary origin [79]. In addition, the 
promoter of some genes such as RASSF1, 1nk4a 
and p16 are methylated in several types of tumors 
[74]. Third characteristic that makes methylated 
genes the suitable markers is that the location on 
the gene, which gets methylated, is determined and 
therefore, designing a pair of primers, the specific 
gene caused methylation, could be easily detected 
[80]. In general, according to the various studies 
conducted so far, it may be claimed that 
methylated genes can be used for detection of 
people at risk of cancer spread. Nowadays, the 
scientists and researchers have considered these 
genes as appropriate tumor markers since they are 
measureable in the samples in which only few 
percentage of tissues have been damaged and also 
at early stages of the disease, which is much 
applicable for timely detection of cancer [73]. 
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